These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 17284697)

  • 1. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery.
    Mangano DT; Miao Y; Vuylsteke A; Tudor IC; Juneja R; Filipescu D; Hoeft A; Fontes ML; Hillel Z; Ott E; Titov T; Dietzel C; Levin J; ;
    JAMA; 2007 Feb; 297(5):471-9. PubMed ID: 17284697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk associated with aprotinin in cardiac surgery.
    Mangano DT; Tudor IC; Dietzel C; ;
    N Engl J Med; 2006 Jan; 354(4):353-65. PubMed ID: 16436767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis.
    Henry D; Carless P; Fergusson D; Laupacis A
    CMAJ; 2009 Jan; 180(2):183-93. PubMed ID: 19050037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of aprotinin on outcome after coronary-artery bypass grafting.
    Shaw AD; Stafford-Smith M; White WD; Phillips-Bute B; Swaminathan M; Milano C; Welsby IJ; Aronson S; Mathew JP; Peterson ED; Newman MF
    N Engl J Med; 2008 Feb; 358(8):784-93. PubMed ID: 18287601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery.
    Karkouti K; Wijeysundera DN; Yau TM; McCluskey SA; Tait G; Beattie WS
    Anesth Analg; 2010 Jan; 110(1):21-9. PubMed ID: 19910626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
    Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
    Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aprotinin during coronary-artery bypass grafting and risk of death.
    Schneeweiss S; Seeger JD; Landon J; Walker AM
    N Engl J Med; 2008 Feb; 358(8):771-83. PubMed ID: 18287600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of aprotinin on adverse clinical outcomes and mortality up to 12 years in a registry of 3,337 patients.
    Olenchock SA; Lee PH; Yehoshua T; Murphy SA; Symes J; Tolis G
    Ann Thorac Surg; 2008 Aug; 86(2):560-6; discussion 566-7. PubMed ID: 18640334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of aprotinin and tranexamic acid on platelet function and postoperative blood loss in cardiac surgery.
    Mengistu AM; Röhm KD; Boldt J; Mayer J; Suttner SW; Piper SN
    Anesth Analg; 2008 Aug; 107(2):391-7. PubMed ID: 18633013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary artery bypass grafting after aprotinin: are we doing better?
    Beckerman Z; Shopen Y; Alon H; Cohen O; Nir RR; Adler Z; Bolotin G
    J Thorac Cardiovasc Surg; 2013 Jan; 145(1):243-8. PubMed ID: 23072702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aprotinin in cardiac surgery patients: is the risk worth the benefit?
    Stamou SC; Reames MK; Skipper E; Stiegel RM; Nussbaum M; Geller R; Robicsek F; Lobdell KW
    Eur J Cardiothorac Surg; 2009 Nov; 36(5):869-75. PubMed ID: 19782574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study.
    Mouton R; Finch D; Davies I; Binks A; Zacharowski K
    Lancet; 2008 Feb; 371(9611):475-82. PubMed ID: 18262039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hemostatic management for cardiac surgical patients in the post-aprotinin era].
    Tanaka K
    Masui; 2009 Mar; 58(3):288-97. PubMed ID: 19306629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risks associated with aprotinin use: a retrospective study of cardiac cases in Nova Scotia.
    Riddell RE; Buth KJ; Sullivan JA
    Can J Anaesth; 2013 Jan; 60(1):16-23. PubMed ID: 23132043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.
    Fergusson DA; Hébert PC; Mazer CD; Fremes S; MacAdams C; Murkin JM; Teoh K; Duke PC; Arellano R; Blajchman MA; Bussières JS; Côté D; Karski J; Martineau R; Robblee JA; Rodger M; Wells G; Clinch J; Pretorius R;
    N Engl J Med; 2008 May; 358(22):2319-31. PubMed ID: 18480196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current antifibrinolytic therapy for coronary artery revascularization.
    Trudell J; McMurdy N
    AANA J; 2008 Apr; 76(2):121-4. PubMed ID: 18478817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aprotinin in cardiac surgery: more risks than usefulness?].
    Bremerich DH; Strametz R; Kirchner R; Moritz A; Zwissler B
    Anaesthesist; 2006 Sep; 55(9):989-92, 994-6. PubMed ID: 16874472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding in cardiac surgery: the use of aprotinin does not affect survival.
    Pagano D; Howell NJ; Freemantle N; Cunningham D; Bonser RS; Graham TR; Mascaro J; Rooney SJ; Wilson IC; Cramb R; Keogh BE
    J Thorac Cardiovasc Surg; 2008 Mar; 135(3):495-502. PubMed ID: 18329459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of aprotinin on short-term and long-term outcomes after coronary artery bypass grafting surgery.
    Wang X; Zheng Z; Ao H; Zhang S; Wang Y; Zhang H; Hu S
    Ann Thorac Surg; 2010 May; 89(5):1489-95. PubMed ID: 20417766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of aprotinin in cardiac surgery: effectiveness and safety in a population-based study.
    Jakobsen CJ; Søndergaard F; Hjortdal VE; Johnsen SP
    Eur J Cardiothorac Surg; 2009 Nov; 36(5):863-8. PubMed ID: 19782573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.